In this Q&A with Pharmaceutical Executive®, Andrew Hopkins, founder and CEO of Exscientia, reveals how artificial intelligence (AI) is currently being utilized in the pharma industry, predictions for where AI can be implemented in the future, and what pharma fears most about AI.
The current vaccine pipeline brings promise of significant global health advancements—yet development gaps remain, and the future delivery challenges must be considered.
Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.
Webinar Date/Time: Tue, Oct 31, 2023 10:00 AM EDT | 9:00 AM CT | 3:00 PM BST | 4:00 PM CEST
Webinar Date/Time: Tuesday, October 24th, 2023 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Webinar Date/Time: Tue, Oct 17, 2023 10:00 AM EDT | 9:00 AM CT | 3:00 PM BST | 4:00 PM CEST
Webinar Date/Time: Tue, Sep 26, 2023 10:00 AM EDT | 9:00 AM CT | 3:00 PM BST | 4:00 PM CEST
In this Q&A, Matt Smith, vice president of research site development, Slope, discusses the competition pharma companies and trial sponsors face when trying to become a sponsor of choice and build trust with sites and patients.
Webinar Date/Time: Thu, Aug 17, 2023 10:00 AM EDT
Expansion aims to continue to create programs that address health and education inequities.
Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically clinical trials.
First guidance in this area from the Agency addresses the unique challenges when designing clinical studies for these drugs
Christon Hill, chief innovation officer, SERB Pharmaceuticals, reveals the demand for antidotes, the process of financial backing, administration needs, as well as antidotes the company is working on, including antidotes for toxins, infectious diseases, biological agents, and drug toxicities.
When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.
O'Neill discusses the company's place in the global market and recent advancements to improve the patient experience.
Panel discusses what real-world evidence—and related patient-reporting technology—need to achieve to better influence payer decision-making.
Webinar Date/Time: Tuesday, March 14 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET
Webinar Date/Time: Tuesday, February 28, 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET
Webinar Date/Time: Tuesday, February 14, 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET
One company pursues a program for a technology they believe is a potential cure for Type 1 diabetes.
Webinar Date/Time: Tuesday, January 31st 2023 | 9 am CT | 10 am ET | 3 pm GMT | 4 pm CET
Webinar Date/Time: Tuesday, January 17th, 2023 at 9 am CT, 10 am ET, 3 pm BST, 4 pm CET
Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.
Webinar Date/Time: Tuesday, Dec 6, 2022, 11am PT | 2pm ET
FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.
